cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-2128Research ArticleКЛИНИЧЕСКИЙ СЛУЧАЙCLINICAL CASEИнфаркт миокарда у молодого мужчины без классических факторов риска атеросклерозаMyocardial infarction in a young man without classical atherosclerotic risk factorsСафароваМ. С.SafarovaM. S.

ординатор отдела проблем атеросклероза

ЕжовМ. В.EzhovM. V.

с.н.с. отдела проблем атеросклероза

ЛупановВ. П.LupanovV. P.

в.н.с. отдела проблем атеросклероза

lypanovvp@mail.ruАлексееваИ. А.AlekseevaI. A.

н.с. отдела проблем атеросклероза

МатчинЮ. Г.MatchinYu. G.

руководитель лаборатории рентгенэндоваскулярных методов диагностики и лечения в амбулаторных условиях

КухарчукВ. В.KukharchukV. V.

руководитель отдела проблем атеросклероза

НИИ кардиологии имени А.Л. Мясникова ФГУ РКНПК МЗ и СР РФ. МоскваA.L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical Complex. Moscow201020102010958690Copyright © Сафарова М.С., Ежов М.В., Лупанов В.П., Алексеева И.А., Матчин Ю.Г., Кухарчук В.В., 20102010Сафарова М.С., Ежов М.В., Лупанов В.П., Алексеева И.А., Матчин Ю.Г., Кухарчук В.В.Safarova M.S., Ezhov M.V., Lupanov V.P., Alekseeva I.A., Matchin Y.G., Kukharchuk V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/2128

.

.

ReferencesKannel W.B., Abbott R.D. Incidence and prognosis of unrecognized myocardial infarction. An update on the Framingham study. N Engl J Med 1984; 311: 1144-7.Kannel W.B., Abbott R.D. Incidence and prognosis of unrecognized myocardial infarction. An update on the Framingham study. N Engl J Med 1984; 311: 1144-7.Chouhan L, Hajar HA, Pomposiello JC. Comparison of thrombolytic therapy for acute myocardial infarction in patients aged < 35 and > 55 years. Am J Cardiol 1993; 71: 157-9.Chouhan L, Hajar HA, Pomposiello JC. Comparison of thrombolytic therapy for acute myocardial infarction in patients aged < 35 and > 55 years. Am J Cardiol 1993; 71: 157-9.Chen L, Chester M, Kaski JC. Clinical factors and angiographic features associated with premature coronary artery disease. Chest 1995; 108: 364-9.Chen L, Chester M, Kaski JC. Clinical factors and angiographic features associated with premature coronary artery disease. Chest 1995; 108: 364-9.Zimmerman FH, Cameron A, Fisher LD, et al. Myocardial infarction in young adults: angiographic characterization, risk factors and prognosis (Coronary Artery Surgery Study Registry). JACC 1995; 26: 654-61.Zimmerman FH, Cameron A, Fisher LD, et al. Myocardial infarction in young adults: angiographic characterization, risk factors and prognosis (Coronary Artery Surgery Study Registry). JACC 1995; 26: 654-61.Yusuf S, Hawken S. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEARTstudy): case-control study. Lancet 2004; 364: 937-52.Yusuf S, Hawken S. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEARTstudy): case-control study. Lancet 2004; 364: 937-52.Friedman GD, Cutter GR, Donahue RP, et al. CARDIA: study design, recruitment, and some characteristics of the examined subjects. J Clin Epidemiol 1988; 41(11): 1105-16.Friedman GD, Cutter GR, Donahue RP, et al. CARDIA: study design, recruitment, and some characteristics of the examined subjects. J Clin Epidemiol 1988; 41(11): 1105-16.Oren A, Vos LE, Uiterwaal CS, et al. The Atherosclerosis Risk in Young Adults (ARYA) study: Rationale and design. Eur J Epidemiol 2003; 18(7): 715-27.Oren A, Vos LE, Uiterwaal CS, et al. The Atherosclerosis Risk in Young Adults (ARYA) study: Rationale and design. Eur J Epidemiol 2003; 18(7): 715-27.Vita JA, Loscalzo J. Shouldering the risk factor burden: infection, atherosclerosis, and the vascular endothelium. Circulation 2002; 106: 164-6.Vita JA, Loscalzo J. Shouldering the risk factor burden: infection, atherosclerosis, and the vascular endothelium. Circulation 2002; 106: 164-6.Ridker PM. Beyond cholesterol: novel risk factors for atherosclerotic disease. Cardiology Rounds 1997; 1(1): 1-8.Ridker PM. Beyond cholesterol: novel risk factors for atherosclerotic disease. Cardiology Rounds 1997; 1(1): 1-8.Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein (a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001; 285: 2481-5.Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein (a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001; 285: 2481-5.Cengel A, Tanindi A. Myocardial infarction in the young. J Postgrad Med 2009; 55(4): 305-13.Cengel A, Tanindi A. Myocardial infarction in the young. J Postgrad Med 2009; 55(4): 305-13.Bostom AG, Cupples АL, Jenner JL, Ordovas J.M. Elevated Plasma Lipoprotein (a) and Coronary Heart Disease in Men Aged 55 Years and Younger. A Prospective Study. JAMA 1996; 276(7): 544-8.Bostom AG, Cupples АL, Jenner JL, Ordovas J.M. Elevated Plasma Lipoprotein (a) and Coronary Heart Disease in Men Aged 55 Years and Younger. A Prospective Study. JAMA 1996; 276(7): 544-8.Ежов М.В. Липопротеид (а) и его роль в развитии коронарных осложнений у больных ишемической болезнью сердца. Автореф дис док мед наук. Москва 2009.Ежов М.В. Липопротеид (а) и его роль в развитии коронарных осложнений у больных ишемической болезнью сердца. Автореф дис док мед наук. Москва 2009.McLean JW, Tomlinson JE, Kuang WJ, et al. cDNA Sequence of human apolipoprotein (a) is homologous to plasminogen. Nature 1987; 330: 132-7.McLean JW, Tomlinson JE, Kuang WJ, et al. cDNA Sequence of human apolipoprotein (a) is homologous to plasminogen. Nature 1987; 330: 132-7.Hoover-Plow JL, Miles LA, Fless GM. Comparison of the lysine binding functions of lipoprotein (a) and plasminogen. Biochemistry 1993; 32(49): 13681-7.Hoover-Plow JL, Miles LA, Fless GM. Comparison of the lysine binding functions of lipoprotein (a) and plasminogen. Biochemistry 1993; 32(49): 13681-7.Keller C. Apheresis in coronary heart disease with elevated Lp (a): a review of Lp (a) as a risk factor and its management. Ther Apher Dial 2007; 11(1): 2-8.Keller C. Apheresis in coronary heart disease with elevated Lp (a): a review of Lp (a) as a risk factor and its management. Ther Apher Dial 2007; 11(1): 2-8.Kamstrup PR, Tybjærg-Hansen A., Steffensen R, et al. Genetically Elevated Lipoprotein (a) and Increased Risk of Myocardial Infarction. JAMA 2009; 301(22): 2331-9.Kamstrup PR, Tybjærg-Hansen A., Steffensen R, et al. Genetically Elevated Lipoprotein (a) and Increased Risk of Myocardial Infarction. JAMA 2009; 301(22): 2331-9.Trégouët DA, König IR, Erdmann J, et al. Genome-wide haplotype association study identifies the SLC22A3-LPAL2- LPA gene cluster as a risk locus for coronary artery disease. Nat Genet 2009; 41: 283-5.Trégouët DA, König IR, Erdmann J, et al. Genome-wide haplotype association study identifies the SLC22A3-LPAL2- LPA gene cluster as a risk locus for coronary artery disease. Nat Genet 2009; 41: 283-5.Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp (a) lipoprotein level and coronary disease. N Engl J Med 2009; 361(26): 2518-28.Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp (a) lipoprotein level and coronary disease. N Engl J Med 2009; 361(26): 2518-28.Pokrovsky SN, Sussekov AV, Afanasieva OI, et al. Extracorporeal immunoadsorption for the specific removal of lipoprotein (a) (Lp (a) apheresis): preliminary clinical data. Chem Phys Lipids 1994; 67-68: 323-30.Pokrovsky SN, Sussekov AV, Afanasieva OI, et al. Extracorporeal immunoadsorption for the specific removal of lipoprotein (a) (Lp (a) apheresis): preliminary clinical data. Chem Phys Lipids 1994; 67-68: 323-30.

The authors declare that there are no conflicts of interest present.